Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination

Infection is the most common cause of mortality early in life, yet the broad potential of immunization is not fully realized in this vulnerable population. Most vaccines are administered during infancy and childhood, but in some cases the full benefit of vaccination is not realized in-part. New adju...

Descripción completa

Detalles Bibliográficos
Autores principales: Dowling, David J., Barman, Soumik, Smith, Alyson J., Borriello, Francesco, Chaney, Danielle, Brightman, Spencer E., Melhem, Gandolina, Brook, Byron, Menon, Manisha, Soni, Dheeraj, Schüller, Simone, Siram, Karthik, Nanishi, Etsuro, Bazin, Hélène G., Burkhart, David J., Levy, Ofer, Evans, Jay T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579132/
https://www.ncbi.nlm.nih.gov/pubmed/36258023
http://dx.doi.org/10.1038/s41598-022-20346-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579132/
https://www.ncbi.nlm.nih.gov/pubmed/36258023
http://dx.doi.org/10.1038/s41598-022-20346-w

Ejemplares similares